NKGen Biotech, Inc. Nyse

NKGN

US65488A1016

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
1.12 ^USD	-0.88%		-11.11%	-86.51%

04-29	Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	CI
04-29	NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP	CI

Graf Acquisition Corp. IV Announces Resignation of Anantha Ramamurti as Chief Financial Officer

May 05, 2022 at 09:14 pm

Graf Acquisition Corp. IV announced the resignation of Anantha Ramamurti as Chief Financial Officer, directors effective May 6, 2022 and officers effective May 11, 2022.

Latest news about NKGen Biotech, Inc.

Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	04-29	CI
NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP	04-28	CI
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	04-18	CI
NKGen Biotech, Inc. announced that it has received $5 million in funding	04-04	CI
NKGen Biotech, Inc. announced that it has received $0.5 million in funding from AJB Capital Investments LLC, Sandia Investment Managment LP, Diametric Capital, LP	03-31	CI
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference	03-25	CI
NKGen Biotech, Inc. announced that it expects to receive $0.33 million in funding from FirstFire Capital Management LLC	03-20	CI
NKGen Biotech, Inc. Announces Resignation of Sangwoo Park as Chairperson of the Board	03-20	CI
NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee	02-08	CI
Exchange-Traded Funds Lower, Equity Futures Flat Pre-Bell Friday	12-29	MT
NKGen Biotech Doses First Patient in Clinical Trial for Alzheimer's Disease Therapy	12-29	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	12-29	MT
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease	12-28	CI
NKGen Biotech Gets Canadian Regulator's Clearance to Study NK Cell Therapy for Alzheimer's	12-27	MT
NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	12-27	CI
NKGen Biotech, Inc.(NasdaqGM:NKGN) added to S&P TMI Index	12-18	CI
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast	27/10/23	MT
US Futures Mixed as Investors Look Toward Personal Income, Consumer Sentiment Reports	27/10/23	MT
Top Premarket Gainers	27/10/23	MT
Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease Conference	26/10/23	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	24/10/23	MT
NKGen Biotech Gets FDA Clearance to Start Alzheimer's Disease Trial; Shares Jump	24/10/23	MT
NKGen Biotech Shares Rise 8% After FDA Clears IND Application for SNK01	24/10/23	DJ
NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	24/10/23	CI
NKGen Biotech, Inc.(NasdaqGM:NKGN) added to NASDAQ Composite Index	04/10/23	CI

NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. It is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimerâs disease (AD) and Parkinsonâs disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. It is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).

Sector

Biotechnology & Medical Research

Calendar

23/05/2024 - International Cell & Gene Therapy China Summit

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B